CVR - Coronavirus Vaccines R&D Roadmap

Vaccinology

Milestones not started
6
Milestones in progress
10
Milestones completed
3
Goals
Strategic goal
3.1

Vaccine attributes

Define goals for broadly protective coronavirus vaccines by establishing a widely agreed upon and vetted set of PPCs and determine use cases for such vaccines.

Milestones
3.1.a
High priority

Preferred Product Characteristics

3.1.b

Use cases

Strategic goal
3.2

New technologies

Leverage new technologies or new approaches to create effective, durable, and safe vaccines that offer broad protection across different coronaviruses.

Milestones
3.2.a

Candidate prioritization

3.2.b
High priority

SARS-CoV-2 mucosal vaccine workshop

3.2.c
Ongoing

Expanded breadth

3.2.d
High priority
Ongoing

Virus and antigen repository

3.2.e

Candidate landscape

3.2.f

Adjuvant repository

3.2.g

Adverse events

3.2.h

Adjuvant use

3.2.i
High priority

Routes of administration

Strategic goal
3.3

Vaccine comparisons

Establish principles that allow for comparisons between vaccines.

Milestones
3.3.a

Harmonized endpoints

3.3.b

Rapid endpoint identification

3.3.c

Clinical trial guidance

Strategic goal
3.4

Regulatory evaluation

Build a foundation for regulatory evaluation of broadly protective coronavirus vaccines.

Milestones
3.4.a

Annual meetings

3.4.b
High priority

Information needs guidance

Strategic goal
3.5

Global needs

Facilitate the development of vaccine candidates with characteristics that meet global needs.

Milestones
3.5.a

LMIC clinical trials

3.5.b

Practical manufacturing systems

3.5.c
High priority

Accessible technology